(SRPT) Sarepta Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US8036071004
Stock: Exon-Skipping Injection, Gene Therapy, Duchenne Treatment
Total Rating 14
Risk 37
Buy Signal -1.68
| Risk 5d forecast | |
|---|---|
| Volatility | 100.0% |
| Relative Tail Risk | -34.1% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.14 |
| Alpha | -105.99 |
| Character TTM | |
|---|---|
| Beta | 1.427 |
| Beta Downside | 0.261 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.72% |
| CAGR/Max DD | -0.58 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
volatile
Description: SRPT Sarepta Therapeutics February 25, 2026
Sarepta Therapeutics (NASDAQ: SRPT) is a commercial-stage biopharma focused on RNA-targeted and gene-therapy treatments for rare muscular dystrophies, most notably Duchenne muscular dystrophy (DMD). Its approved products include EXONDYS 51, VYONDYS 53, AMONDYS 45 (all exon-skipping antisense oligonucleotides) and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.
The company’s pipeline is expanding with SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and several early-stage programs leveraging collaborations with Roche, Arrowhead, Dyno Therapeutics and academic partners such as Duke and Genethon. These partnerships provide both development expertise and potential co-funding, reducing cash burn while accelerating regulatory timelines.
In its most recent Q2-2024 results, Sarepta reported $151 million in total revenue (up 12% YoY) and a cash position of $1.2 billion, giving it >18 months of runway at current burn rates. The DMD market is projected to grow at a CAGR of ~8% through 2030, driven by expanding newborn screening and increasing payer acceptance of high-price gene therapies-key economic tailwinds for SRPT’s product suite.
For deeper insight, you may want to explore ValueRay’s detailed report on SRPT.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: -713.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.09 > 0.02 and ΔFCF/TA -0.58 > 1.0 |
| NWC/Revenue: 65.63% < 20% (prev 123.1%; Δ -57.50% < -1%) |
| CFO/TA -0.06 > 3% & CFO -205.5m > Net Income -713.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (104.8m) vs 12m ago -3.39% < -2% |
| Gross Margin: 59.90% > 18% (prev 0.83%; Δ 5907 % > 0.5%) |
| Asset Turnover: 60.12% > 50% (prev 47.99%; Δ 12.13% > 0%) |
| Interest Coverage Ratio: -32.45 > 6 (EBITDA TTM -757.3m / Interest Expense TTM 24.9m) |
Altman Z'' -5.72
| A: 0.43 (Total Current Assets 2.54b - Total Current Liabilities 1.10b) / Total Assets 3.35b |
| B: -1.46 (Retained Earnings -4.88b / Total Assets 3.35b) |
| C: -0.22 (EBIT TTM -806.7m / Avg Total Assets 3.66b) |
| D: -2.21 (Book Value of Equity -4.88b / Total Liabilities 2.21b) |
| Altman-Z'' Score: -5.72 = D |
Beneish M -3.10
| DSRI: 0.53 (Receivables 398.2m/649.7m, Revenue 2.20b/1.90b) |
| GMI: 1.39 (GM 59.90% / 83.22%) |
| AQI: 1.01 (AQ_t 0.10 / AQ_t-1 0.10) |
| SGI: 1.16 (Revenue 2.20b / 1.90b) |
| TATA: -0.15 (NI -713.4m - CFO -205.5m) / TA 3.35b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of SRPT shares?
As of March 04, 2026, the stock is trading at USD 15.87 with a total of 1,966,343 shares traded.
Over the past week, the price has changed by -15.76%, over one month by -21.75%, over three months by -27.34% and over the past year by -84.32%.
Over the past week, the price has changed by -15.76%, over one month by -21.75%, over three months by -27.34% and over the past year by -84.32%.
Is SRPT a buy, sell or hold?
Sarepta Therapeutics has received a consensus analysts rating of 4.38.
Therefore, it is recommended to buy SRPT.
- StrongBuy: 14
- Buy: 8
- Hold: 4
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SRPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 21.6 | 35.8% |
| Analysts Target Price | 21.6 | 35.8% |
SRPT Fundamental Data Overview March 04, 2026
P/E Forward = 4.2283
P/S = 0.778
P/B = 1.3292
P/EG = 159.25
Revenue TTM = 2.20b USD
EBIT TTM = -806.7m USD
EBITDA TTM = -757.3m USD
Long Term Debt = 1.04b USD (from longTermDebt, two quarters ago)
Short Term Debt = 10.2m USD (from shortTermDebt, two quarters ago)
Debt = 199.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -601.9m USD (from netDebt column, last quarter)
Enterprise Value = 969.9m USD (1.71b + Debt 199.4m - CCE 939.6m)
Interest Coverage Ratio = -32.45 (Ebit TTM -806.7m / Interest Expense TTM 24.9m)
EV/FCF = -3.06x (Enterprise Value 969.9m / FCF TTM -317.4m)
FCF Yield = -32.73% (FCF TTM -317.4m / Enterprise Value 969.9m)
FCF Margin = -14.44% (FCF TTM -317.4m / Revenue TTM 2.20b)
Net Margin = -32.45% (Net Income TTM -713.4m / Revenue TTM 2.20b)
Gross Margin = 59.90% ((Revenue TTM 2.20b - Cost of Revenue TTM 881.5m) / Revenue TTM)
Gross Margin QoQ = 0.53% (prev 62.25%)
Tobins Q-Ratio = 0.29 (Enterprise Value 969.9m / Total Assets 3.35b)
Interest Expense / Debt = 3.79% (Interest Expense 7.57m / Debt 199.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 2.54b / Total Current Liabilities 1.10b)
Debt / Equity = 0.17 (Debt 199.4m / totalStockholderEquity, last quarter 1.14b)
Debt / EBITDA = 0.79 (negative EBITDA) (Net Debt -601.9m / EBITDA -757.3m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -601.9m / FCF TTM -317.4m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.51% (Net Income -713.4m / Total Assets 3.35b)
RoE = -57.52% (Net Income TTM -713.4m / Total Stockholder Equity 1.24b)
RoCE = -35.46% (EBIT -806.7m / Capital Employed (Equity 1.24b + L.T.Debt 1.04b))
RoIC = -26.80% (negative operating profit) (NOPAT -637.3m / Invested Capital 2.38b)
WACC = 10.32% (E(1.71b)/V(1.91b) * Re(11.17%) + D(199.4m)/V(1.91b) * Rd(3.79%) * (1-Tc(0.21)))
Discount Rate = 11.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Fair Price = unknown (Cash Flow -317.4m)
EPS Correlation: 37.50 | EPS CAGR: -16.77% | SUE: -2.08 | # QB: 0
Revenue Correlation: 86.53 | Revenue CAGR: 21.89% | SUE: 1.79 | # QB: 6
EPS next Quarter (2026-06-30): EPS=1.26 | Chg7d=+0.422 | Chg30d=+0.422 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-12-31): EPS=4.35 | Chg7d=+1.247 | Chg30d=+1.247 | Revisions Net=+2 | Growth EPS=+186.1% | Growth Revenue=-21.6%
EPS next Year (2027-12-31): EPS=3.08 | Chg7d=-0.265 | Chg30d=-0.316 | Revisions Net=+0 | Growth EPS=-29.2% | Growth Revenue=-15.5%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)
P/S = 0.778
P/B = 1.3292
P/EG = 159.25
Revenue TTM = 2.20b USD
EBIT TTM = -806.7m USD
EBITDA TTM = -757.3m USD
Long Term Debt = 1.04b USD (from longTermDebt, two quarters ago)
Short Term Debt = 10.2m USD (from shortTermDebt, two quarters ago)
Debt = 199.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -601.9m USD (from netDebt column, last quarter)
Enterprise Value = 969.9m USD (1.71b + Debt 199.4m - CCE 939.6m)
Interest Coverage Ratio = -32.45 (Ebit TTM -806.7m / Interest Expense TTM 24.9m)
EV/FCF = -3.06x (Enterprise Value 969.9m / FCF TTM -317.4m)
FCF Yield = -32.73% (FCF TTM -317.4m / Enterprise Value 969.9m)
FCF Margin = -14.44% (FCF TTM -317.4m / Revenue TTM 2.20b)
Net Margin = -32.45% (Net Income TTM -713.4m / Revenue TTM 2.20b)
Gross Margin = 59.90% ((Revenue TTM 2.20b - Cost of Revenue TTM 881.5m) / Revenue TTM)
Gross Margin QoQ = 0.53% (prev 62.25%)
Tobins Q-Ratio = 0.29 (Enterprise Value 969.9m / Total Assets 3.35b)
Interest Expense / Debt = 3.79% (Interest Expense 7.57m / Debt 199.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -637.3m (EBIT -806.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.32 (Total Current Assets 2.54b / Total Current Liabilities 1.10b)
Debt / Equity = 0.17 (Debt 199.4m / totalStockholderEquity, last quarter 1.14b)
Debt / EBITDA = 0.79 (negative EBITDA) (Net Debt -601.9m / EBITDA -757.3m)
Debt / FCF = 1.90 (negative FCF - burning cash) (Net Debt -601.9m / FCF TTM -317.4m)
Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -19.51% (Net Income -713.4m / Total Assets 3.35b)
RoE = -57.52% (Net Income TTM -713.4m / Total Stockholder Equity 1.24b)
RoCE = -35.46% (EBIT -806.7m / Capital Employed (Equity 1.24b + L.T.Debt 1.04b))
RoIC = -26.80% (negative operating profit) (NOPAT -637.3m / Invested Capital 2.38b)
WACC = 10.32% (E(1.71b)/V(1.91b) * Re(11.17%) + D(199.4m)/V(1.91b) * Rd(3.79%) * (1-Tc(0.21)))
Discount Rate = 11.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.38%
[DCF] Fair Price = unknown (Cash Flow -317.4m)
EPS Correlation: 37.50 | EPS CAGR: -16.77% | SUE: -2.08 | # QB: 0
Revenue Correlation: 86.53 | Revenue CAGR: 21.89% | SUE: 1.79 | # QB: 6
EPS next Quarter (2026-06-30): EPS=1.26 | Chg7d=+0.422 | Chg30d=+0.422 | Revisions Net=-3 | Analysts=7
EPS current Year (2026-12-31): EPS=4.35 | Chg7d=+1.247 | Chg30d=+1.247 | Revisions Net=+2 | Growth EPS=+186.1% | Growth Revenue=-21.6%
EPS next Year (2027-12-31): EPS=3.08 | Chg7d=-0.265 | Chg30d=-0.316 | Revisions Net=+0 | Growth EPS=-29.2% | Growth Revenue=-15.5%
[Analyst] Revisions Ratio: -0.60 (1 Up / 4 Down within 30d for Next Quarter)